Microsize today announced the signing of a long-term supply agreement with
The new supply agreement includes a joint CAPEX investment to build additional dedicated manufacturing suite capacity in 2023 and to qualify a higher-throughput processing train. These investments will allow
TJ Higley, CEO of Microsize, commented, 'We are excited to meet the challenge presented to us by
'We are delighted to continue our relationship with Microsize with today's news. The Microsize team and their expertise have been critical in the history of our pathogen inactivation system over the last two decades, and we look forward to working together into the future,' stated
About Microsize:
For over 30 years, Microsize has been a pioneer in enhancing dissolution and bioavailabilty of Active Pharmaceutical Ingredients (API's) and functional excipients via particle size reduction technologies including milling, micronization and classification. Operating from 100,000 square feet in US-based, state-of-the-art, FDA-inspected GMP facilities, Microsize has the experience and capabilities to rapidly develop, scale up, and process API's and excipients ranging from grams to multi-metric tons, including highly potent compounds ('HPAPI's'). Microsize is THE partner of choice from small biotechs to big pharma to CDMO's, and is recognized for its speed, responsiveness, and high customer-touch business model.
Contact:
TJ Higley CEO
Microsize
Tel: 215-536-5605
Email: tjhigley@microsize.com
(C) 2024 Electronic News Publishing, source